contractpharmaApril 26, 2020
Tag: Ology Bioservices , Veroplex , viral diseases
The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices, a biologics contract development and manufacturing organization (CDMO), to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases.
"The Veroplex platform has the possibility to allow rapid vaccine development for many potential emerging viral infectious diseases," said Peter Khoury, president and chief executive officer, Ology Bioservices. "There is solid evidence that this Vero cell line, when combined with recent innovations in vaccine manufacturing technology, may be valuable in quickly manufacturing vaccines and other biologics in a very small footprint."
CPhI China 2020 To Be Postponed to Dec. 16-18th,
Register as Visitor to the 20th Edition of CPhI China!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: